Literature DB >> 25858321

Downregulation of the DNA repair enzyme apurinic/apyrimidinic endonuclease 1 stimulates transforming growth factor-β1 production and promotes actin rearrangement.

Yuri Sakai1, Tohru Yamamori2, Hironobu Yasui3, Osamu Inanami4.   

Abstract

The DNA repair enzyme apurinic/apyrimidinic endonuclease 1 (APE1) plays a central role in base excision repair and functions as a reductive activator of various transcription factors. Multiple other functionalities have been ascribed to APE1 in addition to these major functions. A recent study showed that APE1 knockdown upregulated the expression of a set of genes related to extracellular matrix (ECM) production, indicating an additional novel biological role for this enzyme. Based on this finding, we have investigated the effect of APE1 downregulation on ECM-related gene expression and its biological consequences. Endogenous APE1 expression was downregulated in human cervical carcinoma HeLa cells and human lung carcinoma A549 cells using siRNA. When the expression of six ECM-related genes (TGFB1, LAMC1, FN1, COL1A1, COL3A1, and COL4A1) was evaluated, we found that APE1 knockdown upregulated the expression of TGFB1 in both cell lines. APE1 downregulation promoted actin rearrangement, inducing F-actin accumulation in HeLa cells and the dissipation of stress fibers in A549 cells. We also discovered that APE1 knockdown enhanced cellular motility in A549 cells, which was suppressed by the inhibition of transforming growth factor (TGF)-β1 signaling. These results suggested that APE1 controls the organization of actin cytoskeleton through the regulation of TGF-β1 expression, providing novel insights into the biological significance of APE1.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  APE1; Actin cytoskeleton; Cellular motility; Extracellular matrix; TGF-β1

Mesh:

Substances:

Year:  2015        PMID: 25858321     DOI: 10.1016/j.bbrc.2015.03.163

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Analysis of the mechanism of radiation-induced upregulation of mitochondrial abundance in mouse fibroblasts.

Authors:  Tohru Yamamori; Tomoya Sasagawa; Osamu Ichii; Mie Hiyoshi; Tomoki Bo; Hironobu Yasui; Yasuhiro Kon; Osamu Inanami
Journal:  J Radiat Res       Date:  2017-05-01       Impact factor: 2.724

2.  Identification of Hub Genes in Idiopathic Pulmonary Fibrosis and NSCLC Progression:Evidence From Bioinformatics Analysis.

Authors:  Yuanshan Yao; Zheng Li; Wen Gao
Journal:  Front Genet       Date:  2022-04-11       Impact factor: 4.772

3.  APE1 controls DICER1 expression in NSCLC through miR-33a and miR-130b.

Authors:  Giulia Antoniali; Emiliano Dalla; Giovanna Mangiapane; Xiaolong Zhao; Xinming Jing; Yi Cheng; Veronica De Sanctis; Dilara Ayyildiz; Silvano Piazza; Mengxia Li; Gianluca Tell
Journal:  Cell Mol Life Sci       Date:  2022-07-25       Impact factor: 9.207

4.  Sulfasalazine, an inhibitor of the cystine-glutamate antiporter, reduces DNA damage repair and enhances radiosensitivity in murine B16F10 melanoma.

Authors:  Masaki Nagane; Eiichi Kanai; Yuki Shibata; Takuto Shimizu; Chie Yoshioka; Takuya Maruo; Tadashi Yamashita
Journal:  PLoS One       Date:  2018-04-12       Impact factor: 3.240

5.  The regulatory role of APE1 in epithelial-to-mesenchymal transition and in determining EGFR-TKI responsiveness in non-small-cell lung cancer.

Authors:  Xiao Yang; Yu Peng; Xuan Jiang; Xianfeng Lu; Wei Duan; Shiheng Zhang; Nan Dai; Jinlu Shan; Yan Feng; Xuemei Li; Yi Cheng; Yuxin Yang; Laura Baugh; Gianluca Tell; Dong Wang; Mengxia Li
Journal:  Cancer Med       Date:  2018-08-14       Impact factor: 4.452

6.  Optimal tumor coverage with different beam energies by IMRT, VMAT and TOMO: Effects on patients with proximal gastric cancer.

Authors:  Sheng-Fang Huang; Jang-Chun Lin; An-Cheng Shiau; Yun-Chih Chen; Ming-Hsien Li; Jo-Ting Tsai; Wei-Hsiu Liu
Journal:  Medicine (Baltimore)       Date:  2020-11-20       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.